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Background. It remains uncertain whether themetabolic syndrome (MS) or insulin resistance contribute to the association between
vitamin D deficiency and obesity. Methods. We conducted a cross-sectional survey of 343 subjects who were overweight or obese.
We analyzed anthropometric data and the presence or absence ofMS. Additionally, we determined 25-hydroxyvitamin D (25OHD)
and insulin concentrations, and the HOMA index was calculated. Chi-square test,Mann-Whitney U test, Student’s t-tests, and
logistic regression analysis were used. Results. The mean age of the patients was 42± 11 years, and 65.9% were women. The mean
BMI was 34.7± 8.3 kg/m2 and 25(OH)D levels were 53.7± 29.8 nmol/L. Forty-six patients (13.4%) had MS. Vitamin D status was
associated with the degree of obesity, especially with a BMI > 40 kg/m2. Patients withMS had lower levels of 25(OH)D than patients
without (43.3±29.0 versus 55.3±29.6mmol/L, resp.), and the odds ratio for hypovitaminosis D was 2.7 (confidence interval (CI),
1.14–6.4) (P = .023) for patients with MS versus patients without MS, irrespective of the degree of obesity. Conclusions. Our data
confirm the association between vitamin D and MS and suggest that this association is independent of the degree of obesity.
1. Introduction
Obesity is a risk factor for many chronic diseases, including
diabetes mellitus, hypertension, dyslipidaemia, and ischemic
heart disease [1, 2]. The association of obesity with these
cardiovascular and metabolic comorbidities is complex, but
the central pattern of fat distribution, a characteristic of
patients with metabolic syndrome (MS), seems to play an
important role [3].
As several studies have reported low serum 25-
hydroxyvitamin D (25(OH)D) levels in obese patients,
vitamin D deficiency is currently considered an obesity
comorbidity [4–7]. However, it remains uncertain whether
the presence of MS and insulin resistance contribute to
the greater rates of hypovitaminosis D observed in obese
individuals.
The present study was undertaken to assess the associ-
ation of vitamin D status with the degree of obesity, the
presence of MS and insulin resistance in overweight and
obese subjects.
2. Materials andMethods
A cross-sectional study was conducted on 343 Caucasian
patients who were overweight or obese and who attended
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Table 1: Patient characteristics (n = 343).
Age (years) 42 ± 11
Men (%) 34.1
Weight (Kg) 92.7 ± 22.4
BMI (Kg/m2) 34.7 ± 8.3
25–29.9 (%) 34.0
30–34.9 (%) 28.9
35–39.9 (%) 15.2
>40 (%) 21.3
Waist (cm) 107 ± 15
Metabolic syndrome (%) 13.4
Glycemia (nmol/L) 5.2 ± 1.36
Insulinemia (uUI/mL) 12.6 ± 8.0
HOMA 2.9 ± 2.1
Calcidiol (nmol/L) 53.7 ± 29.8
Data presented as means and standard deviations and percentages of
patients.
BMI: body mass index.
HOMA: homeostasis model assessment.
the obesity clinic during months of reduced sun exposure
(from October to April). Exclusion criteria were conditions
that could aﬀect vitamin D concentrations, such as malab-
sorption, sunlight allergies, current treatments with calcium
and vitamin D derivatives, treatment with antiepileptic drugs
or rifampicin, kidney or liver insuﬃciency, calcium distur-
bances, and menopause. The study protocol was approved
by the Hospital Ethics Committee, and all patients gave their
informed consent.
In the study visit we recorded anthropometric data
(weight, height, body mass index (BMI), and waist cir-
cumference) and the presence or absence of MS. Waist
measurements were taken using the upper border of the iliac
crest as a reference, in accordance with NIH definitions [8].
Blood pressure was measured twice in seated subjects after a
5min rest using a mercury sphygmomanometer. All analyses
were performed after an overnight fast.
Based on their BMI, the patients were classified as
being overweight (BMI 25–29.9 kg/m2) or having type I
obesity (BMI 30–34.9 kg/m2), type II obesity (BMI 35–
39.9 kg/m2), or type III obesity (>40 kg/m2). The diagnosis
of MS was established according to the Adult Treatment
Panel III (ATP III), which defines MS as the presence of
three or more of the following criteria: abdominal obesity
(waist circumference > 102 cm inmen or >88 cm in women),
triglycerides > 150mg/dL (1.69mmol/L), high density
cholesterol < 40mg/dL (1.04mmol/L) in men or <50mg/dL
(1.30mmol/L) in women, blood pressure > 130/85mmHg
and fasting glucose > 100mg/dL (6.1mmol/L) or previous
diagnosis of diabetes [9].
Serum insulin concentrations were measured by an auto-
mated, solid-phase, two-site chemiluminescent immuno-
metric assay (Immulite 2000, Diagnostic Products Corp., Los
Angeles, CA), with 8% crossreactivity with proinsulin and a
total analytical imprecision less than 7.5% for values between
55 and 2100 pmol/L (7.7 and 291mIU/mL). The HOMA
index was calculated as (glucose (mmol/L) · insulinemia
(µUI/mL))/22.5.
Serum 25(OH)D concentrations were measured using a
commercial radioimmunoassay (Incstard Corp., Stillwater,
MN, USA), with a normal range 25 to 150 nmol/L. 25(OH)D
concentrations were defined as normal (>50 nmol/L), or
hypovitaminosis D (<50 nmol/L) according to Lips criteria
[10].
The data were analyzed using SPSS 17.0 statistical
package (SPSS Inc.). Student’s t-test and the Mann-Whitney
U test were used to analyze independent samples, and the
relationship between qualitative variables was assessed using
a chi-square test. A multiple logistic regression analysis
using a backward method was performed; hypovitaminosis
D was the dependent variable and MS, obesity degree, age,
and HOMA index (categorized into 3 groups according
to quartiles 1 and 3) were the independent variables.
Interactions of MS with obesity degree and HOMA were
assessed.
3. Results
The clinical and biochemical characteristics of the 343
patients are shown in Table 1. The patients with MS were
older (51 ± 9 versus 41 ± 11 years), and they had higher
BMIs (39.4± 8.8 versus 34± 8 kg/m2), waist circumferences
(116 ± 11 versus 105 ± 14 cm), and HOMA indexes (5.3 ±
2.9 versus 2.6 ± 1.8). They presented with lower 25(OH)D
levels than the patients without MS (43.3± 29 versus 55.3±
30 nmol/L). Seventy-eight percent of subjects with MS and
49.2% of subjects without MS presented hypovitaminosis D
(P < .000).
Fifty-two percent of the population studied presented
hypovitaminosis D. The patients with hypovitaminosis D
had higher BMIs (37.4 ± 9.6 versus 31.7 ± 5.3 kg/m2), waist
circumferences (111±15.4 versus 101±12.1 cm), andHOMA
indexes (3.32 ± 2.3 versus 2.6 ± 1.8) than the patients with
normal 25(OH)D levels. The proportion of patients with
the MS was higher in patients with hypovitaminosis D than
in patients with normal vitamin D levels (19.8% versus
6.2%; P < .000). Distribution of vitamin D status according
to the degree of obesity is shown in Table 2. In patients
without MS, the prevalence of hypovitaminosis D exceeded
the prevalence of normal vitamin D levels only when the BMI
was >35 kg/m2, especially in those with a BMI > 40 kg/m2,
while, in patients with MS, there was a predominance of
hypovitaminosis D at all degrees of obesity (data not shown).
When we excluded the patients with a BMI ≥ 40 kg/m2,
the proportions of patients with normal vitamin D levels
and hypovitaminosis D were 58% and 42%, respectively, in
patients without MS and 36.8% and 73.2%, respectively, in
patients with MS (P = .002).
Finally, the multiple logistic regression analysis showed
that both the degree of obesity (P = .001) and the presence
of MS (P = .023) were independently associated with
the presence of hypovitaminosis D. The odds ratio for
hypovitaminosis D was 4.9 (confidence interval (CI), 2–14)
for type III obesity versus overweight patients, while the odds
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Table 2: Vitamin D status according to the degree of obesity.
Obesity degree
Vitamin D status
Normal Hypovitaminosis D
Overweight 20.1% (n = 69) 14.6% (n = 50)
Type I obesity 16.6% (n = 57) 12.2% (n = 42)
Type II obesity 6.7% (n = 23) 8.5% (n = 29)
Type III obesity 3.5% (n = 12) 17.8% (n = 61)
Total 46.9 (n = 161) 53.1 (n = 182)
Data presented as percentages and number of patients. P = .000, according
to chi-square test.
Table 3: Unadjusted and adjusted odds ratios (OR) of having
hypovitaminosis D in the presence of MS.
OR (CI 95%) P
Model 1∗ 3.723 (1.782–7.777) .000
Model 2∗∗ 2.817 (1.287–6.169) .010
Model 3∗∗∗ 2.71 (1.147–6.401) .023
∗
Unadjusted.
∗∗Adjusted for degree of obesity and age.
∗∗∗Adjusted for degree of obesity, age, and HOMA (homeostasis model
assessment).
MS: metabolic syndrome.
ratio for hypovitaminosis D was 2.7 (confidence interval
(CI), 1.14–6.4) for patients with MS versus patients without
MS. HOMA index and interactions of MS with obesity and
HOMA were not significant. Unadjusted and adjusted odds
ratios of having hypovitaminosis D according to the presence
of MS are shown in Table 3.
4. Discussion
The main finding of our study was that the relationship
between vitamin D and MS was independent of the degree
of obesity, adding to our understanding of the relationship
between vitamin D and MS in obese subjects.
The link between hypovitaminosis D and obesity has
been widely demonstrated, particularly in the extremely
obese patients [4–7]. Several hypotheses have been proposed
to explain this association. It has been suggested that obese
subjects have less exposure to sunlight, an inadequate intake
of vitamin D, and decreased bioavailability of vitamin D
due to enhanced uptake and clearance by adipose tissue
[11, 12]. In our study, patients with hypovitaminosis D
had higher BMIs, and the prevalence of hypovitaminosis
D was increased in patients with higher degrees of obesity,
especially those with a BMI > 40 kg/m2. Our data thus
confirm the findings of previous studies where the inverse
association between obesity and hypovitaminosis D was
greater in extremely obese patients [13].
There are compelling data linking hypovitaminosis D
with a higher prevalence of MS in a variety of populations.
In the National Health and Nutrition Examination Survey
(NHANES III) [14], mean 25(OH)D concentrations were
lower in subjects with MS than in subjects without MS
(67.1 versus 75.9 nmol/L), and in another recent study in
adults in the US [15], the odds ratio of having MS in
patients in the highest quintile for vitamin D levels compared
with those in the lowest quintile was 0.26. Similar results
have been found in European [16–19] and Asian [20, 21]
populations. Studies conducted on children, adolescents,
and postmenopausal women also confirm an association of
vitamin D with MS, even after controlling for BMI [22–25].
Studies conducted on obese subjects, however, have shown
conflicting results. Rueda et al. [26] and Hjelmesæth et al.
[27] failed to show a significant association between vitamin
D and metabolic syndrome in severely obese subjects, and
McGill et al. [28] also reported no association between
vitamin D concentrations and the prevalence of metabolic
syndrome in overweight and obese subjects. By contrast,
Botella-Carretero et al. [29] found that extremely obese
subjects withMS had a higher prevalence of hypovitaminosis
D than patients without MS (60.9 versus 33.3%, resp.)
despite having similar BMIs. Moreover, Al-Daghri et al. [30]
recently found that regular exposure to sunlight resulted in
increased levels of vitamin D and a decreased prevalence of
MS in subjects with overweight and obesity. In our study, the
odds ratio for hypovitaminosis D was 2.7 for patients with
MS versus patients without MS, irrespective of the degree of
obesity. These findings provide support for an association
of vitamin D deficiency with MS in overweight and obese
subjects and suggest that this association is independent of
obesity degree.
Another factor that has been linked to vitamin D defi-
ciency is insulin resistance, a key element in the development
of MS [31]. Data from the Framingham Oﬀspring Study
show an inverse association of 25(OH)D with glycemia,
insulin, and the HOMA index after adjustment for BMI
[32]. In another prospective study assessing the relation-
ship between calcidiol and hyperglycemia risk, the authors
confirm an inverse association between calcidiol and the
HOMA index, including after adjustment for BMI, age
and seasonality [18]. In patients with MS, the results are
contradictory. One recent report did not find an association
between 25(OH)D and the HOMA index after adjusting for
BMI [33], while in another study the association between
vitamin D and MS was attenuated after adjustment for the
HOMA index, suggesting that insulin resistance may partly
account for the relation between vitaminD andMS [17]. Our
work showed that patients with vitamin D deficiency had
higher HOMA indexes than patients with normal vitamin
D status. However, this association lost significance in the
multiple logistic regression analysis, suggesting either the
absence of an association between these two variables or a
lack of power to detect an existing association.
The main strength of our work lies in patient selection,
reinforcing the external validity of our findings. First, we
selected those patients who attended the obesity clinic
during months of reduced sunlight, when diﬀerences in sun
exposure between individuals are negligible. Second, all of
our patients were Caucasian, thus limiting the influences
of ethnicity on vitamin D metabolism. Furthermore, we
excluded the presence of renal or liver diseases, several
drugs and malabsorption, which are all known to interfere
with vitamin D metabolism [34–38], and we took into
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account that calcium, phosphorus, PTH, and estrogens may
modulate vitamin D synthesis and alter final 25(OH)D
concentrations [10, 39–41]. Themain limitation of our study
is that the low number of patients did not allow us to analyze
the link between vitamin D and MS in each BMI group
separately. Moreover, since we used a cross-sectional design,
we cannot establish whether the relations between MS and
hypovitaminosis D are causal.
In summary, our study confirms the relationship of
vitamin D status with the degree of obesity and MS and
suggests that the association between vitamin D and MS is
independent of the degree of obesity. Further prospective
studies are needed to assess causality and to determine the
clinical significance of these findings.
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